CY1118412T1 - Ν-[4-(κινολιν-4-υλοξυ)κυκλοεξυλο(μεθυλο)](ετερο)αρυλοκαρβοξα-μιδια ως ανταγωνιστες υποδοχεων ανδρογονων, παραγωγη και χρηση τους ως φαρμακευτικα προϊοντα - Google Patents

Ν-[4-(κινολιν-4-υλοξυ)κυκλοεξυλο(μεθυλο)](ετερο)αρυλοκαρβοξα-μιδια ως ανταγωνιστες υποδοχεων ανδρογονων, παραγωγη και χρηση τους ως φαρμακευτικα προϊοντα

Info

Publication number
CY1118412T1
CY1118412T1 CY20161101343T CY161101343T CY1118412T1 CY 1118412 T1 CY1118412 T1 CY 1118412T1 CY 20161101343 T CY20161101343 T CY 20161101343T CY 161101343 T CY161101343 T CY 161101343T CY 1118412 T1 CY1118412 T1 CY 1118412T1
Authority
CY
Cyprus
Prior art keywords
derivatives
quinolin
yloxy
cyclohexyl
methyl
Prior art date
Application number
CY20161101343T
Other languages
English (en)
Inventor
Duy Nguyen
Hermann Künzer
Gimenez Hortensia Faus
Benjamin Bader
Silke Köhr
Martin Fritsch
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48699019&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1118412(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of CY1118412T1 publication Critical patent/CY1118412T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η εφεύρεση αναφέρεται στα Ν-[4-(κινολιν-4-υλοξυ)κυκλοεξυλο(μεθυλο)] (έτερο) αρυλοκαρβοξαμίδια, στα ενδιάμεσα και στις μεθόδους για την παραγωγή τους, στη χρήση τους για τη θεραπεία και/ή πρόληψη ασθενειών και στη χρήση τους για την παραγωγή φαρμακευτικών προϊόντων και στη χρήση αυτών για την θεραπεία και/ή πρόληψη ασθενειών, ιδιαίτερα των υπερπολλαπλασιαστικών ασθενειών.
CY20161101343T 2012-06-26 2016-12-23 Ν-[4-(κινολιν-4-υλοξυ)κυκλοεξυλο(μεθυλο)](ετερο)αρυλοκαρβοξα-μιδια ως ανταγωνιστες υποδοχεων ανδρογονων, παραγωγη και χρηση τους ως φαρμακευτικα προϊοντα CY1118412T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12004764 2012-06-26
PCT/EP2013/063118 WO2014001247A1 (en) 2012-06-26 2013-06-24 N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products
EP13731325.0A EP2864291B1 (en) 2012-06-26 2013-06-24 N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products

Publications (1)

Publication Number Publication Date
CY1118412T1 true CY1118412T1 (el) 2017-06-28

Family

ID=48699019

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161101343T CY1118412T1 (el) 2012-06-26 2016-12-23 Ν-[4-(κινολιν-4-υλοξυ)κυκλοεξυλο(μεθυλο)](ετερο)αρυλοκαρβοξα-μιδια ως ανταγωνιστες υποδοχεων ανδρογονων, παραγωγη και χρηση τους ως φαρμακευτικα προϊοντα

Country Status (41)

Country Link
US (1) US9428460B2 (el)
EP (1) EP2864291B1 (el)
JP (1) JP6181172B2 (el)
KR (1) KR20150023880A (el)
AP (1) AP3919A (el)
AR (1) AR091565A1 (el)
AU (1) AU2013283543B2 (el)
BR (1) BR112014032538A2 (el)
CA (1) CA2877786C (el)
CL (1) CL2014003443A1 (el)
CO (1) CO7170167A2 (el)
CR (1) CR20140593A (el)
CU (1) CU20140144A7 (el)
CY (1) CY1118412T1 (el)
DK (1) DK2864291T3 (el)
DO (1) DOP2014000295A (el)
EA (1) EA028063B1 (el)
EC (1) ECSP14032516A (el)
ES (1) ES2609455T3 (el)
HK (1) HK1206346A1 (el)
HR (1) HRP20161745T1 (el)
HU (1) HUE032306T2 (el)
IL (1) IL236146B (el)
JO (1) JO3342B1 (el)
LT (1) LT2864291T (el)
MA (1) MA37700B1 (el)
ME (1) ME02590B (el)
MX (1) MX2014016054A (el)
NZ (1) NZ703100A (el)
PE (1) PE20150154A1 (el)
PH (1) PH12014502869A1 (el)
PL (1) PL2864291T3 (el)
PT (1) PT2864291T (el)
RS (1) RS55500B1 (el)
SG (1) SG11201408254UA (el)
SI (1) SI2864291T1 (el)
TN (1) TN2014000532A1 (el)
TW (1) TWI600646B (el)
UA (1) UA115447C2 (el)
UY (1) UY34881A (el)
WO (1) WO2014001247A1 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160145803A (ko) * 2014-04-22 2016-12-20 님버스 아이리스 인코포레이티드 Irak 억제제 및 이의 용도
UY36391A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
KR20190003686A (ko) * 2016-05-04 2019-01-09 브리스톨-마이어스 스큅 컴퍼니 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
KR20190004742A (ko) 2016-05-04 2019-01-14 브리스톨-마이어스 스큅 컴퍼니 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328821A (en) 1991-12-12 1994-07-12 Robyn Fisher Cold and cryo-preservation methods for human tissue slices
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
EP1296953A2 (en) 2000-06-23 2003-04-02 Eli Lilly And Company Methods and compounds for inhibiting mrp1
CN100415720C (zh) 2001-06-22 2008-09-03 麒麟医药株式会社 喹啉衍生物和喹唑啉衍生物以及含有这些化合物的药物组合物
CA2488785C (en) 2002-09-11 2012-07-03 Kureha Chemical Industry Company, Limited Amine compound and use thereof
US20050227932A1 (en) 2002-11-13 2005-10-13 Tianbao Lu Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
DE602004022633D1 (de) 2003-01-30 2009-10-01 Boehringer Ingelheim Pharma 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EP1725238A4 (en) 2004-03-17 2009-04-01 Glaxo Group Ltd ACETYLCHOLINE M 3 MUSCARINIC RECEPTOR ANTAGONISTS
SE0401342D0 (sv) 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds
WO2005117570A1 (en) 2004-05-27 2005-12-15 Jack Saffron Feeding dish to prevent pest infestation
RU2007119427A (ru) 2004-11-09 2008-12-20 СмитКлайн Бичем Корпорейшн (US) Соединения, являющиеся ингибиторами гликогенфосфорилазы, и фармацевтические композиции на их основе
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
GB0509224D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of intracellular enzymatic activity
GB0509227D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
US20060293341A1 (en) 2005-06-23 2006-12-28 Vrej Jubian Alkyl sulfonamide derivatives
WO2007091694A1 (en) 2006-02-06 2007-08-16 Showa Denko K.K. Whitening dermatological preparations
CA2655128A1 (en) 2006-06-08 2007-12-21 Array Biopharma Inc. Quinoline compounds and methods of use
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
WO2008064432A1 (en) 2006-12-01 2008-06-05 The University Of Sydney Polycyclic molecular compounds
CA2696430C (en) 2007-08-16 2015-10-06 Boehringer Ingelheim International Gmbh Quinazolinedione chymase inhibitors
UY31432A1 (es) 2007-10-26 2009-05-29 Compuestos de diarilhidantoina
CA2723617A1 (en) 2008-05-14 2009-11-19 Amgen Inc. Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
EP2349328A1 (en) 2008-10-01 2011-08-03 Ludwig Institute For Cancer Research Methods for the treatment of cancer
CN102471327A (zh) 2009-07-21 2012-05-23 吉里德科学公司 黄病毒科病毒的抑制剂
US20120238533A1 (en) 2009-09-11 2012-09-20 Bayer Pharma Aktiengesellschaft (Heteroarylmethyl) Thiohydantoins as anticancer drugs
US9050334B2 (en) 2010-07-16 2015-06-09 Innov88 Llc MIF inhibitors and their uses

Also Published As

Publication number Publication date
EP2864291B1 (en) 2016-10-05
IL236146A0 (en) 2015-02-01
PH12014502869B1 (en) 2015-02-23
HK1206346A1 (en) 2016-01-08
MA37700B1 (fr) 2018-03-30
NZ703100A (en) 2016-10-28
EA028063B1 (ru) 2017-10-31
PH12014502869A1 (en) 2015-02-23
US9428460B2 (en) 2016-08-30
CO7170167A2 (es) 2015-01-28
MX2014016054A (es) 2015-04-10
JO3342B1 (ar) 2019-03-13
EA201500039A1 (ru) 2015-06-30
CA2877786A1 (en) 2014-01-03
ME02590B (me) 2017-06-20
PE20150154A1 (es) 2015-02-19
SI2864291T1 (sl) 2017-01-31
JP2015521641A (ja) 2015-07-30
BR112014032538A2 (pt) 2017-06-27
JP6181172B2 (ja) 2017-08-16
ECSP14032516A (es) 2015-12-31
TW201400460A (zh) 2014-01-01
CA2877786C (en) 2020-08-25
DK2864291T3 (en) 2017-01-16
US20150191431A1 (en) 2015-07-09
KR20150023880A (ko) 2015-03-05
TWI600646B (zh) 2017-10-01
RS55500B1 (sr) 2017-05-31
LT2864291T (lt) 2017-01-10
AR091565A1 (es) 2015-02-11
UY34881A (es) 2014-01-31
EP2864291A1 (en) 2015-04-29
DOP2014000295A (es) 2015-01-31
AU2013283543B2 (en) 2017-11-02
TN2014000532A1 (en) 2016-03-30
MA20150269A1 (fr) 2015-08-31
HUE032306T2 (en) 2017-09-28
CL2014003443A1 (es) 2015-06-26
ES2609455T3 (es) 2017-04-20
AU2013283543A1 (en) 2015-01-29
HRP20161745T1 (hr) 2017-02-24
UA115447C2 (uk) 2017-11-10
PT2864291T (pt) 2017-01-06
CU20140144A7 (es) 2015-08-27
IL236146B (en) 2018-05-31
PL2864291T3 (pl) 2017-07-31
AP2014008141A0 (en) 2014-12-31
WO2014001247A1 (en) 2014-01-03
CN104684896A (zh) 2015-06-03
SG11201408254UA (en) 2015-01-29
CR20140593A (es) 2015-02-16
AP3919A (en) 2016-11-30

Similar Documents

Publication Publication Date Title
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
CY1121694T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
CY1120969T1 (el) Παραγωγα κινοξαλινης χρησιμα ως τροποποιητες fgfr κινασης
CY1119200T1 (el) Νεα παραγωγα βενζιμιδαζολιου ως ερ4 ανταγωνιστες
CY1123649T1 (el) Παραγωγα ιμιδαζολινης, μεθοδοι παρασκευης αυτων και εφαρμογες αυτων στην ιατρικη
CY1120390T1 (el) Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
CY1118869T1 (el) Παραγωγα αμιδο σπειροκυκλικου αμιδιου και σουλφοναμιδιου
CY1119151T1 (el) Ν-(4-(αζαϊνδαζολ-6-υλ)-φαινυλ)-σουλφοναμιδiα και η χρηση τους ως φαρμακα
CY1118412T1 (el) Ν-[4-(κινολιν-4-υλοξυ)κυκλοεξυλο(μεθυλο)](ετερο)αρυλοκαρβοξα-μιδια ως ανταγωνιστες υποδοχεων ανδρογονων, παραγωγη και χρηση τους ως φαρμακευτικα προϊοντα
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CY1120715T1 (el) Παραγωγα ετεροαρυλιου βουτανικου οξεος ως αναστολεις lta4h
CY1119047T1 (el) Υποκατεστημενα βενζαμιδια με δραστικοτητα εναντι υποδοχεων ερ4
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
UY34543A (es) Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica.
EA201691796A1 (ru) П-замещенные асимметричные мочевины и их применение в медицине
CY1118852T1 (el) Παραγωγα πυριμιδοοξαζοσινης ως αναστολεις της mtor
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
CY1121313T1 (el) Φαρμακευτικη διεργασια και ενδιαμεσα
CY1121388T1 (el) Παραγωγα βενζυλυδροξειδιου, παρασκευη αυτων και θεραπευτικη χρηση αυτων
TH1401007761A (th) N-[4-(ควิโนลิน-4-อิลอกซี)ไซโคลเฮกซิล(เมธิล)](เฮเทอโร)อะริลคาร์บอกซาไมด์ ในฐานะเป็นแอนโดรเจน รีเซฟเตอร์ แอนตาโกนิสท์, การผลิต และ การใช้ของสิ่งเหล่านั้นในฐานะเป็นผลิตภัณฑ์ซึ่งมีคุณสมบัติเป็นยา
MX2016010549A (es) Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas.